To Global Liver Institute President and CEO Donna Cryer, the recent EASL Guidelines on use of non-invasive testing (NITs) represent a major breakthrough in GLI’s ongoing “Beyond the Biopsy” campaign. In this one-on-one interview with Roger Green, Donna discusses the rigorous, multidimensional approach that GLI has taken to championing NITs in drug development and patient treatment. The conversation eventually pivots to a discussion of the benefits, drawbacks and challenges associated with gaining a cirrhosis indication for drugs in development.
